The multifaceted role of sustained IL-10 in simultaneously activating and expanding cytotoxic tumor-specific CD8+ T cells while suppressing tumor-associated inflammation has positioned it as a cytokine of significant clinical interest in cancer immunotherapy. The gene discussed is CD8A; the disease is neoplasm.